QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer
Status: Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 03 Sep 2019
Price : $35 *
At a glance
- Drugs Aldoxorubicin (Primary) ; ALT 803 (Primary) ; Avelumab (Primary) ; Brachyury peptide vaccine (Primary) ; CD16 and interleukin 2 expressing natural killer cells-NantKwest (Primary) ; Cisplatin (Primary) ; Cyclophosphamide (Primary) ; ETBX 011 (Primary) ; ETBX-051 (Primary) ; ETBX-061 (Primary) ; Fluorouracil (Primary) ; GI 4000 (Primary) ; Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors NantKwest
- 23 Aug 2019 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 08 Aug 2018 Planned initiation date changed from 1 Jul 2018 to 1 Sep 2018.
- 05 Jul 2018 Planned initiation date changed from 1 Jun 2018 to 1 Jul 2018.